AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04851132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.
Study NCT04851132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
Study NCT05669118 — intervention group
Intervention type: PROCEDURE
Intervention: Tooth Autotransplantation
Description: Place another tooth in the place of the newly extracted tooth in the same patient.
Study NCT05669118 — intervention group
Intervention type: PROCEDURE
Intervention: Immediate implant
Description: Place a dental implant immediately after tooth extraction.
Study NCT05370898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caltrate D
Description: Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
Study NCT05370898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caltrate D
Description: Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
Study NCT05394753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for mood disorders
Description: The group-based UP is structured and manualized and consists of 9 1.5 hours weekly sessions (90-min, 18 participants in each group). The group-based UP is a course consisting of components of psycho-education about mood disorders, cognitive and behavioural skills, and relapse prevention and is adapted for the non-clinical population in the current study. The UP will be led and delivered by trained therapists.
Study NCT05370898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medicine prescription
Description: The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Study NCT05370898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Study NCT04985045 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
Study NCT05215028 — intervention group
Intervention type: DEVICE
Intervention: web-application
Description: web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
Study NCT00236379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Target oral dose of 20 milligrams per day for 6 months
Study NCT00236379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Target oral dose of 6 milligrams per day for for 6 months
Study NCT04706897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, ketamine and lidocaine
Description: A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
Study NCT04706897 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
Study NCT06071897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monoclonal antibodies GD2
Description: Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy
Study NCT04922229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT
Description: This is the standard of care for this diagnosis
Study NCT04922229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
Study NCT04839822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: edupression.com®
Description: Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, App) at any time.
Study NCT04839822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health tips
Description: Interventions that do not directly target depression: general health tips (diet, lifestyle, smoking, etc.), occupational health interventions (back pain prevention, breaks,...), etc.
Study NCT04839822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: Quizzes and surveys for course monitoring (including suicidality), but without extensive reports.
Study NCT04839822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Popular psychological interventions
Description: Popular psychological interventions, which have not been shown to be effective in studies: Affirmation phrases, motivational sayings and quotes (known also from calendars), tests (e.g., Rorschach interpretation), exercises (emotion recognition of faces), multimedia content (pleasant music, landscape images, interviews of famous people with depression), etc.
Study NCT05691751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary unilateral total knee arthroplasty with limited application of tourniquet
Description: the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be cruciate scarifying cemented DePuy Synthes PFC Sigma without resurfacing of the patella, intramedullary guides will be used for the femoral and tibial cuts as seen appropriate by the surgeon, however, the application time of the tourniquet during surgery will be as the allocation of each patient imply.
Study NCT05691751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary unilateral total knee arthroplasty with full application of tourniquet
Description: the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be
Study NCT05057689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine (4 mcg/kg)
Description: Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
Study NCT05057689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl (2 mcg/kg)
Description: Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
Study NCT05057689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam (5 mg/kg)
Description: Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
Study NCT05833477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin treatment three times per week for three weeks
Study NCT05728736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 25 mg
Description: Lemborexant 25mg will be taken nightly for two consecutive nights.
Study NCT05728736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken nightly for two consecutive nights
Study NCT05426408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging to study coronary microvascular dysfunction
Description: Myocardial perfusion mapping will be investigated after administration of adenosine
Study NCT06028789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample test
Description: The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)
Study NCT06028789 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracic Aortic Surgery
Description: Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
Study NCT06173479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HeBSaPU
Description: HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
Study NCT06173479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeBSaPU
Description: HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
Study NCT04549896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Surgeon will perform a CT scan before the surgery procedure (CTO PCI) in order to increase the success rate of the surgery.
Study NCT04549896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No CT scan
Description: The surgery procedure (CTO PCI) will be performed following the standard of care, meaning that the surgeon will not perform a CT scan before the surgery procedure.
Study NCT06387628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: LM-108, 10mg/kg, d1, q6w
Study NCT06387628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240 mg, d1, q3w
Study NCT06387628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2, d1, 8 , q3w
Study NCT06387628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 125 mg/m2, d1, 8 , q3w
Study NCT05165927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR
Description: BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
Study NCT06003920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process group
Description: The medical student process group served as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
Study NCT05810766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement
Description: MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
Study NCT05810766 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy
Description: Hot pack for 15 minutes
Study NCT05166330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol equal ratio
Description: 5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
Study NCT05166330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol 1:3 ratio
Description: 15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
Study NCT04716660 — intervention group
Intervention type: OTHER
Intervention: Sensory block level check
Description: Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
Study NCT05654142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Base intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages
Study NCT05654142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages
Study NCT04880109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX-115
Description: Oral administration of APX-115 100 mg capsule once daily for 14 days
Study NCT04880109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo capsule once daily for 14 days
Study NCT05654142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
Study NCT05654142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
Study NCT05110690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
Study NCT05110690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Optimization
Description: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Study NCT05804370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleolan
Description: Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
Study NCT04706299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
Study NCT04706299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
Study NCT05189223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief, values based intervention for early buprenorphine treatment
Description: The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
Study NCT05189223 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief, values based intervention for early buprenorphine treatment
Description: The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
Study NCT05189223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine, methadone, or naltrexone prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
Study NCT05147571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Responsive stimulation
Description: The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
Study NCT05147571 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
Study NCT06528847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.
Study NCT04218786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: The tablet will be given once daily for the span of the study
Study NCT04218786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The tablet will be given once daily for the span of the study